Chat with us, powered by LiveChat
Lhasa Logo

December 2023

Safeguarding Pharmaceutical Development: The Importance of Early Risk Mitigation

Innovate /

Ensuring the safety and efficacy of active pharmaceutical ingredients (APIs) is of paramount importance. A critical aspect of this process involves the identification and mitigation of potentially mutagenic impurities, like nitrosamines. In this blog, we will explore the significance of risk mitigation at the early stages of API development and introduce a cutting-edge solution, Zeneth, […]

Safeguarding Pharmaceutical Development: The Importance of Early Risk Mitigation Read More »

Mitigating the risks of NDSRI’s through data sharing

Discuss, Innovate /

At Lhasa, we believe in the transformative power of knowledge sharing as the driving force to support the global challenge of nitrosamine risk assessment. Through data sharing and industry collaboration, we empower members to further understand the risks associated with their potential nitrosamine impurities. The Vitic Complex Nitrosamines initiative, launched in 2021 in response to

Mitigating the risks of NDSRI’s through data sharing Read More »

Q&A deep dive with Martin Walter: How to establish AI limits for NDSRIs

Discuss /

Building on the success of our recent webinar, How to establish acceptable intake (AI) limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs), we’re thrilled to present a follow-up that brings you closer to the insightful discussions that unfolded during the interactive Q&A session. In this blog, we’ve gathered questions posed during the webinar and curated written

Q&A deep dive with Martin Walter: How to establish AI limits for NDSRIs Read More »